The association between Cytomegalovirus co-infection with Pneumocystis pneumonia and mortality in immunocompromised non-HIV patients

Basit Öğe Kaydı
dc.contributor.authorEkren, Pervin Korkmaz
dc.contributor.authorToreyin, Zehra Nur
dc.contributor.authorNahid, Payam
dc.contributor.authorDoskaya, Mert
dc.contributor.authorCaner, Ayse
dc.contributor.authorTurgay, Nevin
dc.contributor.authorZeytinoglu, Aysin
dc.contributor.authorToz, Seray
dc.contributor.authorBacakoglu, Feza
dc.contributor.authorGuruz, Yuksel
dc.contributor.authorErensoy, Selda
dc.date.accessioned2019-10-27T10:01:06Z
dc.date.available2019-10-27T10:01:06Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description.abstractIntroduction Impact of Cytomegalovirus (CMV) co-infection pneumonia in non-HIV patients with Pneumocystis jirovecii pneumonia (PCP) is unclear. Objectives Methods The aim of our study was to determine whether CMV co-infection is associated with an increased risk of mortality. Our study was conducted at Ege University Hospital, Turkey. We used molecular assays to diagnose Pneumocystis jirovecii in respiratory samples, and CMV in both respiratory and blood samples. We compared morbidity and mortality stratified by CMV co-infection status. Results Conclusion Between 2009 and 2015, 43 patients (mean age: 56.7 +/- 15.3 years) were diagnosed with PCP. Only 3 of 43 patients had received PCP prophylaxis. We microbiologically confirmed CMV co-infection in 28 of 43 (65.1%) patients. Acute respiratory distress syndrome (ARDS) and requirement of mechanical ventilation were more common in the CMV co-infection group (P = .019 and P = .031 respectively), and duration of intensive care unit was also longer (P = .006). In univariate analyses, mortality at 30 days was higher in the CMV co-infection group as compared to the group with PCP alone (78.6% and 46.7% respectively; P = .046). In multivariate analyses, mortality was independently associated only with the presence of ARDS [OR: 6.22 95% CI 1.3-29.32] and the association with CMV co-infection was no longer significant [OR: 2.6 95% CI 0.49-13.72, P = .257]. The risk of mortality appears to be increased in the setting of CMV and PCP co-infection in HIV-uninfected immunocompromised patients. PCP prophylaxis use was lower than expected, suggesting low physician awareness of the risks of PCP in this population.en_US
dc.identifier.doi10.1111/crj.12961en_US
dc.identifier.endpage2597en_US
dc.identifier.issn1752-6981
dc.identifier.issn1752-699X
dc.identifier.issue11en_US
dc.identifier.pmid30244544en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage2590en_US
dc.identifier.urihttps://doi.org/10.1111/crj.12961
dc.identifier.urihttps://hdl.handle.net/11454/29802
dc.identifier.volume12en_US
dc.identifier.wosWOS:000450262800008en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofClinical Respiratory Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcytomegalovirus (CMV)en_US
dc.subjectHIV-negative (non-HIV)en_US
dc.subjectmortalityen_US
dc.subjectPneumocystis jiroveciien_US
dc.subjectpneumoniaen_US
dc.titleThe association between Cytomegalovirus co-infection with Pneumocystis pneumonia and mortality in immunocompromised non-HIV patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu